Associated Papers
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
40200811 (PubMed )
Supplement: cbm-22-237-s001.pdf
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
36430388 (PubMed )
Supplement: ijms-23-13898-s001.zip › ijms-1981646-supplementary.pdf
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
32976510 (PubMed )
Supplement: pone.0237802.s009.zip › Table_9_Accuracy_Short_Variant_Line_Data.xlsx › sheet_1
Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W et al.
Cancer Science, 2019
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Cortot AB et al.
Journal of the National Cancer Institute, 2017
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
Dixit A et al.
Biophysical Journal, 2009
Select a paper to view details